TOP > 外国特許検索 > METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO DESIRED CELL TYPE

METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO DESIRED CELL TYPE

外国特許コード F160008885
整理番号 (S2015-0777-N0)
掲載日 2016年10月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP057420
国際公開番号 WO 2016143826
国際出願日 平成28年3月9日(2016.3.9)
国際公開日 平成28年9月15日(2016.9.15)
優先権データ
  • 特願2015-046318 (2015.3.9) JP
発明の名称 (英語) METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO DESIRED CELL TYPE
発明の概要(英語) Provided is a method for predicting the directionality of cell differentiation caused by induced expression of a transcription factor and differentiating mammalian pluripotent stem cells into a desired cell type. The inventors newly created a human gene expression correlation matrix using human cells and furthermore introduced a transcription factor cocktail selected from the matrix into human pluripotent stem cells, and thereby confirmed that differentiation into a desired cell type is possible and perfected the present invention.
特許請求の範囲(英語) [claim1]
1. Either of the (1)-(5) below the process which introduces copying factor of 1 or more into the versatile characteristic trunk cell of mammalian origin is included, the versatile characteristic trunk cell the method of differentiating in the nervous system cell.
(1) copying factor of 5 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(2) copying factor of 4 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(3) copying factor of 3 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(4) copying factor of 2 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(5) copying factor of 1 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
[claim2]
2. As for the aforementioned nervous system cell, the method statement differentiating in the claim 1 which includes the motor nerve.
[claim3]
3. As for the aforementioned motor nerve, the method statement differentiating in the claim 1 which is the cell where it exists in the motor nerve or 2.
[claim4]
4. Either of the (1)-(5) below the versatile characteristic trunk cell of the mammalian origin which includes the copying factor of 1 or more in the nervous system cell the differentiation possible nervous system cell differentiation induction medicine.
(1) copying factor of 5 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(2) copying factor of 4 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(3) copying factor of 3 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(4) copying factor of 2 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
(5) copying factor of 1 where it is selected from NEUROG1, NEUROG2, NEUROG3, NEUROD1 and NEUROD2
[claim5]
5. As for the aforementioned nervous system cell, in the claim 4 which is the peripheral characteristic motor nerve the differentiation induction medicine of statement.
[claim6]
6. As for the aforementioned motor nerve, in the claim 4 which is the cell which exists in the motor nerve or 5 the differentiation induction medicine of statement.
[claim7]
7. As for the aforementioned copying factor, mRNA and synthesis mRNA, either of the claim 4-6 which is nuclear acid or the protein in 1 the differentiation induction medicine of statement.
[claim8]
8. Either of the (1)-(5) below the process which introduces copying factor of 1 or more into the versatile characteristic trunk cell of mammalian origin is included, the versatile characteristic trunk cell the liver bud cell and/or the method of differentiating in the liver cell.
(1) copying factor of 1 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(2) copying factor of 2 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(3) copying factor of 3 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(4) copying factor of 4 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(5) copying factor of 5 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
[claim9]
9. Either of the (1)-(5) below the versatile characteristic trunk cell of the mammalian origin which includes the copying factor of 1 or more the liver bud cell and/or in the liver cell the differentiation possible liver bud cell and/or the liver cell differentiation induction medicine.
(1) copying factor of 1 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(2) copying factor of 2 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(3) copying factor of 3 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(4) copying factor of 4 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
(5) copying factor of 5 where it is selected from TGIF, TCF4, PITX2, SALL4 and MEIS1
[claim10]
10. The (1)- below (7) in each case the process which introduces copying factor of 1 or more into the versatile characteristic trunk cell of mammalian origin is included, the versatile characteristic trunk cell the hemotopoiesis trunk cell and/or the method of differentiating in the blood cell.
(1) copying factor of 1 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(2) copying factor of 2 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(3) copying factor of 3 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(4) copying factor of 4 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(5) copying factor of 5 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(6) copying factor of 6 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(7) Copying factor of 7 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
[claim11]
11. The (1)- below (7) in each case the versatile characteristic trunk cell of the mammalian origin which includes the copying factor of 1 or more the hemotopoiesis trunk cell and/or in the blood cell the differentiation possible hemotopoiesis trunk cell and/or the blood type cell differentiation induction medicine.
(1) copying factor of 1 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(2) copying factor of 2 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(3) copying factor of 3 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(4) copying factor of 4 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(5) copying factor of 5 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(6) copying factor of 6 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
(7) Copying factor of 7 where it is selected from CDYL2, ETS2, SPI1, OVOL2, CDX2, CEBPB and SALL4
[claim12]
12. The process which introduces SOX9 which is copying factor into the versatile characteristic trunk cell of mammalian origin is included, the versatile characteristic trunk cell the method of differentiating in the cartilage cell.
[claim13]
13. The versatile characteristic trunk cell of the mammalian origin which includes SOX9 which is copying factor in the cartilage cell the differentiation possible cartilage cell differentiation induction medicine.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KEIO UNIVERSITY
  • 発明者(英語)
  • KO MINORU
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close